Last checked at 7 Apr 2016 13:44
7 April 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Issue of Equity from Exercise of Share Options
Maryland, USA - MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, today announces the issue and allotment of 37,968 new common stock of $0.01 per share each in the Company ("Common Stock") pursuant to the exercise of certain share options.
Application has been made for the new Common Stock to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place at 8.00 a.m. on 12 April 2016. The new Common Stock will rank pari passu with the existing Common Stock of the Company.
Following the exercise of options and Admission, the Company will have 43,508,429 shares of Common Stock in issue, none of which is in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
- Ends -
For further information please contact:
MaxCyte | +1 301 944 1660 |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | |
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking)
| +44 (0) 20 7886 2500
|
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
Mary-Jane Elliott Chris Welsh Lindsey Neville |
About MaxCyte
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.
MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers with an established regulatory path.
MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.
For more information visit http://www.maxcyte.com/